Navigation Links
Mediware to Report Third Quarter 2008 Financial Results on Tuesday, May 6th
Date:4/29/2008

Conference Call Scheduled For May 6th At 10:00 am ET, 9:00 am CT

LENEXA, Kan., April 29 /PRNewswire-FirstCall/ -- Mediware Information Systems, Inc. (Nasdaq: MEDW) will release its financial results for the third quarter of fiscal year 2008 on Tuesday, May 6th. The Company will host a teleconference call at 10:00 am Eastern Time (9:00 am Central Time) that day to discuss the results. There will be a question-and-answer session directly following the presentation of the results.

To participate in the teleconference, please call toll-free 888-869-1189 (direct dial 706-643-5902) five minutes before the scheduled start in order to register for the call. The conference ID is: 44903038. You may also register in advance of the call online by going to: http://www.directeventreg.com/registration/event/44903038.

A replay of the call will be available after the call's completion for 5 days at 800-642-1687 (direct dial 706-645-9291). The conference ID is 44903038. After 5 days, the replay will be available on the company's web site: http://www.mediware.com.

About Mediware

Mediware delivers blood and medication management software systems that encapsulate information supporting patient therapies, reinforce patient safety practices and improve efficiencies to lower costs. Mediware's customers include prestigious hospitals, clinics, correctional institutions, blood centers and other public and private health care institutions throughout the world. For more information about Mediware's products and services, visit the company's web site at http://www.mediware.com.

Certain statements in this press release may constitute "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, as the same may be amended from time to time (the "Act") and in releases made by the SEC from time to time. Such forward-looking statements are not based on historical facts and involve known and unknown risks, uncertainties and other factors disclosed in the Company's Annual Report on Form 10-K for the year ended June 30, 2007, which may cause the actual results of the Company to be materially different from any future results expressed or implied by such forward-looking statements. The Company disclaims any obligation to update its forward-looking statements.

Contact: John Van Blaricum Thomas Redington

VP, Marketing & Communications 203 222-7399

913 307-1017 212 926-1733

http://www.mediware.com http://www.redingtoninc.com


'/>"/>
SOURCE Mediware Information Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Mediware Board Authorizes $4 Million Stock Buyback
2. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
3. Replidyne to Report First Quarter 2008 Earnings
4. Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth
5. SuperGen Reports 2008 First Quarter Financial Results
6. Emisphere Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements
7. Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance
8. Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder
9. CV Therapeutics Reports 2008 First Quarter Financial Results
10. Caliper Life Sciences Reports West Coast Consolidation of Operations
11. Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... 20, 2017 , ... G&L Scientific Inc, a leading provider ... ), has announced the opening of new offices in Cambridge, Massachusetts, strengthening and ... This is the latest step in G&L’s expansion of its global clinical consulting ...
(Date:1/21/2017)... , Jan. 20, 2017 Aratana Therapeutics, Inc. ... focused on the licensing, development and commercialization of innovative ... Best Company in North America ... the award based on the FDA approval of ... tablets), ENTYCE ® (capromorelin oral solution) and NOCITA ...
(Date:1/20/2017)... http://www.Financialbuzz.com - According ... causes of death worldwide. There were 8.2 million cancer ... related deaths increased gradually over time, the death rates ... various cancers continues to drive demand of biological therapies ... Market Insights, Inc. cancer biological therapy market size was USD ...
(Date:1/19/2017)... SHANGHAI , Jan. 19, 2017 /PRNewswire -- ... medical device open-access capability and technology platform, today ... a leading biology focused preclinical drug discovery contract ... Biosciences will become a wholly-owned subsidiary of WuXi, ... core competences and providing greater services. The acquisition ...
Breaking Biology Technology:
(Date:1/12/2017)... PUNE, India , January 12, 2017 A ... 2015 - 2022," projects that the global biometric technology market is expected to generate ... to 2022. Continue Reading ... ...      (Logo: ...
(Date:1/11/2017)... , Jan. 11, 2017  Michael Johnson, co-founder of Visikol Inc. ... Group, Inc., has been named to the elite "Forbes 30 Under ... one of 600 people in 20 fields nationwide to be recognized ... the 15,000 applicants were selected. ... He is currently a PhD candidate at Rutgers University. ...
(Date:1/6/2017)... Colo. , Jan. 5, 2017  SomaLogic ... the "Digital Life Alliance" established by iCarbonX, the ... 2015 to build a "Global Digital Health Ecosystem ... on a combination of individual,s biological, behavioral and ... the agreement between the companies, SomaLogic will provide ...
Breaking Biology News(10 mins):